Xcout Intel
Focal Therapeutics, Inc.
Focal Therapeutics provides the Focal One robotic system, which utilizes high-intensity focused ultrasound (HIFU) technology to non-invasively target and ablate prostate tissue for prostate cancer patients. The system is designed for urologists to precisely treat targeted lesions while sparing healthy surrounding tissue and minimizing side effects.
Subscribe to see Focal Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Focal Therapeutics, Inc. at a glance
Focal Therapeutics, Inc. is a medical device company headquartered in United States. It has raised at least $11M across the 3 funding rounds on record. Its most recent funding round raised $48,880 in July 2016.
Focal Therapeutics, Inc. funding rounds
At least $11M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $48,880 | — | |
| SEC Form D filing | $3.8M | — | |
| Series A | $7.1M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Focal Therapeutics, Inc. competitors
A few of Focal Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Focal Medical develops and manufactures the Focal One HIFU Robotic System, a non-invasive medical device that utilizes high-intensity focused ultrasound technology to precisely target and ablate prostate tissue. The company serves urologists and healthcare facilities by providing equipment for prostate cancer management that preserves healthy surrounding tissue and minimizes side effects for patients.
SpectraCure is a medical technology company that develops a precision treatment system for localized prostate cancer and other internal solid tumors. The company utilizes photodynamic therapy (PDT) combined with a proprietary dose-planning platform to offer targeted, minimally invasive treatments for prostate cancer patients.
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
URO-1, Inc. is a privately held medical device company established in 2017 and based in Greensboro, North Carolina. The company develops and manufactures surgical solutions and instruments for biopsy procedures, specifically focusing on prostate and soft tissue cancer diagnostics.
Francis Medical, Inc. develops medical technology for targeted tissue ablation, including the Vanquish System designed for water vapor prostate treatment.
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Get Focal Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Focal Therapeutics, Inc. in Xcout Intel
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access